Amedica Corporation to Review Third Quarter 2017 Financial Results and Host Conference Call

SALT LAKE CITY, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Amedica Corporation (Nasdaq:AMDA), an innovative biomaterial company that develops and manufactures silicon nitride as a platform for biomedical applications, announced today that on November 21, 2017, the company will host a conference call and audio webcast with Dr. Sonny Bal, CEO of Amedica Corporation, to review its third quarter 2017 financial results.

Details related to this call are as follows:

Date:  November 21, 2017

Time: 9 AM MST

Conference ID:  13673764

Dial-in:   Toll free 877 524 8416
                  International - +1-412-902-1028

Webcast: Investor section of the company’s website

For those who are not available to listen to the live webcast, a digital replay will be archived on the investor relations section of the Amedica website under Events & Presentations.

About Amedica Corporation

Amedica is focused on the development and application of spinal interbody implants made with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing implants for other biomedical applications, such as wear- and corrosion-resistant hip and knee bearings, and dental implants. The Company’s products are manufactured in its ISO 13485 certified manufacturing facility, and it has a partnership with Kyocera, one of the world’s largest ceramic manufacturers. Amedica’s FDA-cleared and CE-marked spine products are currently marketed in the U.S. and select markets in Europe and South America through its distributor network, and OEM and private label partnerships.

For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated within this press release. A discussion of those risks and uncertainties can be found in Amedica’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on September 20, 2017, and in Amedica’s other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.

Contacts:
Amedica IR
801-839-3502
IR@amedica.com

Released November 15, 2017